Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARSE PNEUDOS study
2022-003582-38Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Jan 2023
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of meropenem, piperacillin + tazobactam, ceftriaxone and benzylpenicillin in pneumonia and bacterial pneumonia (4 cohorts), sponsored by CHU Nîmes. Started Jan 2023; status: completed.
02
Drugs
meropenempiperacillin + tazobactamceftriaxonebenzylpenicillin
03
Conditions
pneumoniabacterial pneumonia
Beyond the preview
Go deeper on 2022-003582-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003582-38.